State Street Corp Ultragenyx Pharmaceutical Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

A detailed history of State Street Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, State Street Corp holds 2,664,077 shares of RARE stock, worth $118 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,664,077
Previous 2,697,101 1.22%
Holding current value
$118 Million
Previous $111 Million 33.5%
% of portfolio
0.01%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$40.21 - $59.36 $1.33 Million - $1.96 Million
-33,024 Reduced 1.22%
2,664,077 $148 Million
Q2 2024

Aug 14, 2024
SELL
$37.42 - $51.61 $5.77 Million - $7.96 Million
-154,149 Reduced 5.41%
2,697,101 $111 Million
Q1 2024

May 15, 2024
SELL
$43.02 - $53.69 $17.3 Million - $21.5 Million
-401,252 Reduced 12.34%
2,851,250 $133 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $21.7 Million - $33.7 Million
684,644 Added 26.66%
3,252,502 $156 Million
Q3 2023

Nov 14, 2023
BUY
$34.92 - $46.66 $3.58 Million - $4.78 Million
102,408 Added 4.15%
2,567,858 $91.5 Million
Q2 2023

Aug 14, 2023
SELL
$37.35 - $52.15 $10.5 Million - $14.6 Million
-280,257 Reduced 10.21%
2,465,450 $114 Million
Q1 2023

May 15, 2023
SELL
$36.99 - $48.71 $7.29 Million - $9.6 Million
-197,060 Reduced 6.7%
2,745,707 $110 Million
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $12.9 Million - $17.8 Million
383,223 Added 14.97%
2,942,767 $136 Million
Q3 2022

Nov 15, 2022
BUY
$39.96 - $66.14 $4.09 Million - $6.76 Million
102,236 Added 4.16%
2,559,544 $106 Million
Q2 2022

Aug 15, 2022
BUY
$45.8 - $85.4 $23.3 Million - $43.4 Million
508,624 Added 26.1%
2,457,308 $147 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $16.8 Million - $22.8 Million
269,843 Added 16.07%
1,948,684 $142 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $15.1 Million - $18 Million
204,976 Added 13.91%
1,678,841 $141 Million
Q3 2021

Nov 15, 2021
BUY
$77.92 - $102.4 $8.02 Million - $10.5 Million
102,990 Added 7.51%
1,473,865 $133 Million
Q2 2021

Aug 16, 2021
SELL
$92.19 - $115.71 $22.1 Million - $27.8 Million
-239,964 Reduced 14.9%
1,370,875 $131 Million
Q1 2021

May 17, 2021
SELL
$106.9 - $167.73 $7 Million - $11 Million
-65,460 Reduced 3.91%
1,610,839 $183 Million
Q4 2020

Feb 16, 2021
SELL
$84.4 - $177.39 $11.9 Million - $25 Million
-140,693 Reduced 7.74%
1,676,299 $232 Million
Q3 2020

Nov 10, 2020
SELL
$72.98 - $90.0 $11.8 Million - $14.5 Million
-161,252 Reduced 8.15%
1,816,992 $149 Million
Q2 2020

Aug 14, 2020
SELL
$46.91 - $78.22 $11.8 Million - $19.6 Million
-251,107 Reduced 11.26%
1,978,244 $155 Million
Q1 2020

May 11, 2020
BUY
$33.8 - $62.9 $75.4 Million - $140 Million
2,229,351 New
2,229,351 $99.1 Million

Others Institutions Holding RARE

# of Institutions
325
Shares Held
85.6M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.1B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email